Assessment of Maropitant Citrate Effectiveness as an Intraoperative Analgesic Through Monitoring Parasympathetic Tone Activity in Female Dogs Undergoing Ovariohysterectomy
Authors:
- Areli Ramírez-CastilloARAreli Ramírez-Castillo
- Claudia InterlandiCIClaudia Interlandi
- Agatha Elisa Miranda CortésACAgatha Elisa Miranda Cortés
- Navid Ziaei-DarounkolaeiNZNavid Ziaei-Darounkolaei
- Alejandro Casas-AlvaradoAlejandro Casas-Alvarado
- Alejandro Jiménez-YedraAJAlejandro Jiménez-Yedra
- Ismael Hernández-AvalosIsmael Hernández-Avalos
Open Access
- 10 May 2026
- journal article
- research article
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (5) , 463
Abstract
Maropitant has been proposed as an adjunct for pain relief in dogs undergoing surgeries like ovariohysterectomy (OVH), but its effectiveness has not yet been definitively proven. This study aimed to assess the intraoperative analgesic effect of intravenously administered maropitant citrate at a constant rate infusion through monitoring parasympathetic tone activity in female dogs undergoing OVH. Thirty healthy females of various breeds, with an average age of 3.8 ± 2.7 years, an average weight of 16.75 ± 10.68 kg, were randomly assigned to two treatment groups. The group receiving maropitant (GMaro, n = 15) was given a 1 mg kg−1 maropitant bolus intravenously (IV), followed by a continuous infusion of 100 mcg kg−1 min−1. The lidocaine group (GLido, n = 15) received a 2 mg/kg lidocaine IV bolus, with subsequent infusion at 50 mcg kg−1 min−1. Cardiorespiratory variables and the PTA index were evaluated at 11 anesthetic time points. Overall, cardiovascular variables such as Heart Rate (HR) and systolic arterial pressure (SAP) significantly decreased during anesthesia induction in the GMaro (p = 0.0001; p = 0.01, respectively) and in GLido (p = 0.01). Differences between groups during induction were observed in HR (p = 0.03), SAP (p = 0.04), and mean arterial pressure (MAP) (p = 0.03). MAP showed significant changes from baseline at the start of surgery and during clamping in both GMaro (p = 0.03) and GLido (p = 0.003). Regarding ventilatory variables—pulse oximetry (SpO2), respiratory rate (RR), inspired oxygen fraction (FiO2), end-tidal CO2 (EtCO2)—no group differences were found, but RR (GMaro; p = 0.001, GLido; p = 0.0001) and SpO2 (GMaro; p = 0.004, GLido; p = 0.04) differed significantly from baseline due to the controlled clinical setting. During anesthesia maintenance, end-tidal isoflurane (ETIso) increased significantly in the GLido (p = 0.009), with no difference between groups (p = 0.94). Finally, only the PTA energy variable showed a significant decrease in the GMaro (p = 0.0006), and a significant difference in this parameter was observed during right ovarian pedicle manipulation between groups (p = 0.02). In conclusion, continuous intravenous infusion of maropitant citrate at 100 mcg kg−1 h−1 effectively reduced the sympathetic response related to nociception, similar to lidocaine, in healthy female dogs undergoing OVH.Keywords
This publication has 74 references indexed in Scilit:
- Evaluation of the antinociceptive effect of NK-1 antagonist - maropitant, in different doses in dogs undergoing ovariohysterectomy - a prospective randomized clinical studyVeterinary Research Communications, 2025
- Adjuvant Analgesics in Acute Pain ManagementVeterinary Clinics of North America: Small Animal Practice, 2019
- Physiology of PainCritical Care Nursing Clinics of North America, 2017
- Intravenous lidocaineBest Practice & Research Clinical Anaesthesiology, 2017
- Pathophysiology of painDisease-a-Month, 2013
- Multimodal Pain Management in Veterinary Medicine: The Physiologic Basis of Pharmacologic TherapiesVeterinary Clinics of North America: Small Animal Practice, 2008
- Efficacy and Safety of a Neurokinin-1 Receptor Antagonist in Postmenopausal Women With Overactive Bladder With Urge Urinary IncontinenceJournal of Urology, 2006
- Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivoBrain Research, 1996
- Distribution of the substance P receptor (NK-1 receptor) in the central nervous systemMolecular Brain Research, 1993
- Biochemical characterization and autoradiographic localization of central substance P receptors using [125I]physalaeminBrain Research, 1985